Aceva, LLC marketed Sugar Balance supplement with unapproved diabetes and blood sugar drug claims, FDA says.
What happened
In August 2021, FDA reviewed Aceva's website and social media pages, which direct consumers to the website to buy Sugar Balance, and found claims that the product improves insulin sensitivity, blood sugar control, and A1c levels and helps get diabetes under control. FDA says those claims make Sugar Balance an unapproved "new drug"—not generally recognized as safe and effective for those uses—and a misbranded drug that lacks adequate directions for safe lay use. The FTC also reviewed the websites in August 2021 and raised concerns that the diabetes claims may not be substantiated.
What FDA found
FDA says the website and social media claims show Sugar Balance is intended to treat or prevent disease, which makes it a drug.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]FDA says Sugar Balance is a "new drug"—not generally recognized as safe and effective for its claimed uses—and was sold without FDA approval.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]FDA says Sugar Balance is misbranded—it lacks adequate directions for safe use by a layperson—because it is intended for diseases that are not suitable for self-treatment without a licensed practitioner.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5FDA says introducing the misbranded drug into interstate commerce violates the law.
FD&C Act section 301(a) [21 U.S.C. 331(a)]The FTC says Aceva must stop claiming Sugar Balance can prevent, treat, or cure diabetes unless it has competent and reliable scientific evidence, including well-controlled human clinical studies.
FTC Act, 15 U.S.C. § 41 et seq.
What FDA wants
FDA asks Aceva to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations and prevent recurrence, with documentation, or explain any delay. The FTC separately asks for notice within 15 working days of actions taken to address its concerns.
Who should pay attention
- dietary supplement brands making blood sugar or diabetes claims
- online marketers and social media advertisers of supplements
- companies selling supplements through websites and social media
This is a summary. Read the original letter on fda.gov.